We are live on ! Find out more
MCM

M28 Capital Management Portfolio holdings

AUM $47.2M
1-Year Est. Return 32.31%
This Fund
S&P 500
This Quarter Est. Return
+7.35%
1 Year Est. Return
+32.31%
3 Year Est. Return
+200.03%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.8M
AUM Growth
+$6.59M
Cap. Flow
+$2.72M
Cap. Flow %
2.84%
Top 10 Hldgs %
99.15%
Holding
13
New
–
Increased
3
Reduced
5
Closed
1
Avg Time Held
2.8 quarters
Top 10 Avg Time Held
2.8 quarters
Top 20 Avg Time Held
2.8 quarters

Top Buys

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$11.4M
2
BBIO icon
BridgeBio Pharma
BBIO
+$489K
3
CRIS icon
Curis
CRIS
+$241K

Top Sells

Rank Stock Value
1
VERV icon
Verve Therapeutics
VERV
+$2.9M
2
TGTX icon
TG Therapeutics
TGTX
+$2.54M
3
ATRA icon
Atara Biotherapeutics
ATRA
+$2.1M
4
WVE icon
Wave Life Sciences
WVE
+$993K
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$780K

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Financials 2.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IVVD icon
1
Invivyd
IVVD
$213M
$28.9M 30.22%
9,248,250
+2,850,000
+45% +$11.4M
2021 Q4
3 quarters
WVE icon
2
Wave Life Sciences
WVE
$682M
$28.8M 30.08%
7,982,204
-300,000
-4% -$993K
2021 Q4
3 quarters
RCKT icon
3
Rocket Pharmaceuticals
RCKT
$281M
$10.6M 11.09%
665,880
-50,000
-7% -$780K
2021 Q4
3 quarters
STOK icon
4
Stoke Therapeutics
STOK
$1.6B
$6.71M 7%
522,550
-4,600
-0.9% -$73.3K
2021 Q4
3 quarters
BBIO icon
5
BridgeBio Pharma
BBIO
$12.8B
$5.1M 5.33%
513,300
+47,100
+10% +$489K
2021 Q4
3 quarters
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.27M 4.46%
61,200
– –
2021 Q4
3 quarters
CRIS icon
7
Curis
CRIS
$1.63M
$3.14M 3.27%
11,205
+597
+6% +$241K
2021 Q4
3 quarters
VERV icon
8
DELISTED
Verve Therapeutics
VERV
$3.01M 3.14%
87,600
-90,900
-51% -$2.9M
2022 Q1
2 quarters
CYPH icon
9
Cypherpunk Technologies Inc
CYPH
$317M
$2.35M 2.45%
266,440
– –
2021 Q4
3 quarters
TGTX icon
10
TG Therapeutics
TGTX
$8.48B
$2.01M 2.09%
338,800
-387,400
-53% -$2.54M
2021 Q4
3 quarters
PRQR icon
11
ProQR Therapeutics
PRQR
$230M
$745K 0.78%
1,001,800
– –
2022 Q1
2 quarters
NEXI icon
12
DELISTED
NexImmune, Inc. Common Stock
NEXI
$74K 0.08%
5,338
– –
2021 Q4
3 quarters
ATRA icon
13
Atara Biotherapeutics
ATRA
$95.2M
– –
-10,770
Closed -$2.1M –

Similar funds

OGC
One68 Global Capital New York $47.2M AUM 6.52% 1-Year Est. Return
BJB
Broadhurst Jeffrey B $47M AUM
JCM
JAT Capital Management Greenwich, Connecticut $47.4M AUM 177.04% 1-Year Est. Return
FDG
Financial Discovery Group Atlanta, Georgia $46.9M AUM
BAM
BTS Asset Management Lincoln, Massachusetts $47.4M AUM 1.28% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
NPCM
New Paradigm Capital Management Great Falls, Virginia $46.8M AUM
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

M28 Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, M28 Capital Management held 13 positions worth $95.8M, up 7.4% from $89.2M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

M28 Capital Management's Q3 2022 filing shows 3 increased, 5 reduced and 1 closed positions. The largest sale was Verve Therapeutics, an estimated $2.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

  • M28 Capital Management added most to Invivyd in Q3 2022, an estimated $11.4M increase.
  • M28 Capital Management's biggest Q3 2022 reduction was Verve Therapeutics, cutting an estimated $2.9M.
  • M28 Capital Management fully exited Atara Biotherapeutics in Q3 2022, selling an estimated $2.1M.
  • M28 Capital Management's ten largest holdings make up 99% of its $95.8M portfolio in Q3 2022.
  • M28 Capital Management opened 0 new positions and closed 1 in Q3 2022.
  • M28 Capital Management's portfolio value rose 7.4% quarter-over-quarter to $95.8M.

Based on M28 Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.